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Background: Low back pain is an important public health problem that is associated with poor quality of life and
disability. Among the electrophysical treatments, interferential current (IFC) has not been studied in patients with
low back pain in a high-quality randomised controlled trial examining not only pain, but pain mechanisms and
function.
Methods/design: A three-arm randomised controlled trial with patient and assessor blinded to the group
allocation. One hundred fifty patients with chronic, nonspecific low back pain from outpatient physical therapy
clinics in Brazil. The patients will be randomly allocated into 3 groups (IFC 1 kHz, IFC 4 kHz or Placebo IFC). The
interferential current will be applied three days per week (30 minutes per session) over four weeks. Primary
outcome: Pain intensity. Secondary outcomes: The pressure pain threshold, global impression of recovery, disability,
function, conditioned pain modulation and temporal summation of pain, discomfort caused by the current. All
outcomes will be measured at 4 weeks and 4 months after randomisation. The between-group differences will be
calculated by using linear mixed models and Tukey’s post-hoc tests.
Discussion: The use of a placebo group and double-blinding assessor and patients strengthen this study. The
present study is the first to compare different IFC carrier frequencies in patients with chronic low back pain.
Trial registration: Brazilian Registry of Clinical Trials: RBR-8n4hg2
Keywords: Low Back Pain, Electric Stimulation, Central Nervous System Sensitization, Central Sensitization, Physical
Therapy ModalitiesBackground
Low back pain is an important public health issue that
directly affects an individual’s quality of life and activ-
ities of daily living (ADLs) [1]. Low back pain is also re-
sponsible for many absences from work and has high
worldwide socioeconomic costs [2]. The prognosis with
acute and persistent low back pain is favourable, and
the condition improves or resolves in the majority
within the first 6 weeks. However, low to moderate pain* Correspondence: liebano@gmail.com
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reproduction in any medium, provided the orlevels and disability can persist in patients who become
chronic [3].
Inefficient endogenous pain control and central sensi-
tivity are important characteristics in patients with low
back pain [4]. Prolonged afferent nociceptive impulses
may lead to increased excitability of the central sensory
neurons and changes in their plasticity that lead to
hypersensitivity resulting in an exaggerated response to
pain [5]. Increasing evidence supports the clinical signifi-
cance of the central sensitisation in patients with unex-
plained chronic pain; therefore, reduction in central
sensitisation should be targeted for the treatment of
these patients. The use of conservative therapies such asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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manual therapy in experimental models suggests that
these treatments can reduce the central sensitization in
animals and could desensitise the central nervous system
(CNS) in humans [6,7].
The treatment of chronic low back pain aims to re-
duce pain and disability [8]. Exercise is widely prescribed
for treating patients with chronic low back pain [9].
However, patients with low back pain may have signifi-
cant pain that limits their physical capacity, making it dif-
ficult to exercise [10]. Therefore, the use of electrophysical
agents to decrease pain could enable these patients to
participate in an exercise program at an earlier stage of re-
covery [10]. Among the electrotherapeutical resources,
interferential current (IFC) has been studied for the treat-
ment of acute [11] and chronic low back pain [10]. A re-
cent systematic review concluded that when combined
with other treatments, such as exercises and massage, IFC
demonstrates advantages over placebo and non-treatment
control groups in reducing the intensity of pain associated
with musculoskeletal disorders [12]. However, little evi-
dence has indicated that the use of IFC alone can re-
duce the intensity of pain [12], disability or use of
analgesics, or improve function in patients with chronic
low back pain [10].
Despite various adjustments to the amplitude-
modulated frequency (AMF) often used in clinical prac-
tice to treat different injury or disease stages, studies
have indicated that AMF does not influence hypoalgesia
in healthy individuals [13,14], which suggests that the
main parameter that should be adjusted is the carrier
frequency of the current to affect the pain inhibitory
mechanisms [13]. A 2 kHz carrier frequency is often
used to strengthen the muscles, and a 4 kHz frequency
is used to produce analgesia. However, this conduct is
based on therapists’ personal observations, equipment
manuals [15] and not on controlled studies. Only one
study [16] has compared the effect of the carrier fre-
quencies of the interferential current on the pressure
pain threshold in healthy individuals. This study demon-
strated that a 1 kHz frequency provides a higher
hypoalgesic response compared with 8 kHz or 10 kHz
during and after IFC stimulation. However, the evidence
on the use of IFC alone for decreasing pain remains in-
sufficient. In addition, chronic low back pain appears to
be linked to central sensitisation and a deficiency in the
activation of the central pain inhibition mechanisms.
Thus, these patients could possibly benefit from the use
of IFC to relieve their symptoms. For these reasons, we
decided to conduct a prospective randomized controlled
study to assess the effects of IFC on pain at rest and dur-
ing movement, and the disability in patients with
chronic low back pain. This study also aims to assess if
the use of IFC would reactivate the innate mechanism ofconditioned pain modulation and decrease the central
hypersensitivity in chronic low back pain patients.
Methods /design
Study design
This is a three-arm randomised controlled trial with pa-
tient and assessor blinded to the group allocation.
Figure 1 provides a flowchart of the study.
Participants, therapists, centres
Patients seeking physical therapy treatment at the clinic
of the Universidade Cidade de São Paulo - UNICID and
the Centro de Especialidades Médicas de Guarulhos -
CEMEG through medical referral who present nonspecific
low back pain for at least 3 months and with a minimum
pain intensity of 3 in the 0–10 pain numeric rating
scale (NRS-Brazilian-Portuguese version) [17] during
the last 7 days will be included in the study. Patients of
both genders with ages ranging from 18 to 80 years old
will be included. Patients with severe spinal disorders
such as fractures, tumours and inflammatory diseases
including ankylosing spondylitis; patients with nerve
root disorders confirmed by neurological exams (herni-
ated disks and spondylolisthesis with neurological in-
volvement, spinal canal stenosis and others); patients
suffering from neurological diseases, severe cardiopul-
monary diseases, pregnancy, infection or skin lesions at
the current application site, cancer, or changes in sensi-
tivity and allergy in the region of electrode positioning;
and patients who require artificial cardiac pacemakers
will be excluded.
Participants will be assessed by the researcher respon-
sible for the assessments during the study to verify that
they fit the inclusion criteria. If eligible, they will be in-
formed of the study objectives. They will then sign an
informed consent form to participate in the study. The
present study was approved by the Research Ethics
Committees of Universidade Cidade de São Paulo and
Centro de Especialidades Médicas de Guarulhos.
Due to the nature of the intervention, only the therap-
ist responsible for application of IFC will be aware about
group allocation; the assessor and the participants will
be blinded to the group allocation. To keep the evaluator
blind to the study groups, the device will be covered
with a dark cloth.
Intervention
Each participant will be randomly allocated to one of 3
groups: Group IFC 1 kHz (n = 50), Group IFC 4 kHz
(n = 50) and a Placebo IFC Group (n = 50). All partici-
pants will receive 30 minutes of current stimulation
(the current amplitude will not be increased for the
participants in the placebo group) 3 times per week on
alternate days for 4 weeks for a total of 12 sessions.
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Figure 1 Flowchart of the study.
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that produces a medium-frequency alternating current
(Neurovector, Indústria Brasileira de Equipamentos
Médicos - IBRAMED®, Amparo, Brazil). This equipment
was developed exclusively for the present study and is
not commercially available. The technique used will in-
volve a bipolar mode with 2 channels located 5 cm from
the L3 and L5 spinous processes. The following parame-
ters will be employed: current carrier frequency
according to the patient group (1 or 4 kHz); AMF = 100
Hz; Sweep = 50 Hz; 1:1 swing pattern and 30 minutes of
stimulation.
The procedures for the placebo group will be similar
to those of the other groups; however, the current ampli-
tude will not be increased. The patients will be informed
that they may or may not feel any sensation at the appli-
cation site of the electrodes [13]. For the active groups,
the therapist will increase the current amplitude until
the participant reports feeling a strong but comfortable
tingling. Every 5 minutes, the therapist will ask each par-
ticipant whether the “strong but comfortable tingling”
remains. In case of sensory habituation, the current
amplitude will be increased until the participant reaches
the previous sensation. After ending the application, the
patient will wait for 20 minutes for the necessary mea-
surements be taken.Outcome measures
Primary outcome
Pain intensity after all treatment sessions and 4 months
after randomisation.
Secondary outcomes
(1) pressure pain threshold; (2) current discomfort; (3)
disability; (4) global impression of recovery; (5) func-
tional performance; (6) conditioned pain modulation
and pain temporal summation; and (7) analgesic use
measured in all time-points.
Measurement instruments
Pain numerical rating scale (NRS)
Pain intensity will be assessed using the pain numerical
rating scale (NRS) [18], which assesses the level of pain
intensity perceived by the patient through an 11-point
scale (ranging from 0 to 10), with 0 indicating “no pain”
and 10 indicating the “worst possible pain”. The pain as-
sessment will be carried out verbally with the patient
reporting the pain intensity. This instrument has been
translated and cross-culturally adapted for the Brazilian
population [17].
The pain will be assessed prior to applying the current,
at 30 minutes of treatment with the current still on and
20 minutes after the current is turned off. This variable
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the follow-up examination after 4 months.
Pressure pain threshold (PPT)
The pressure pain threshold (PPT) will be measured
using a Somedic digital pressure algometer (Somedic
Inc., Hörby, Sweden). Assessments will be performed
prior to application of the current, immediately after the
30th minute of stimulation and 20 minutes after the ses-
sion has ended. This assessment will be performed in
the first and last sessions.
Hygienisation with soap and water will be performed
at the assessed sites. After cleaning the skin, the areas to
which the algometer will be attached will be marked
with a tape measure and a pen. Two points will be
marked bilaterally: the first located 5 cm lateral to the
L3 spinous process [19] and the second located 5 cm lat-
eral to the L5 spinous process [20]. A point, to be used
as a control, will also be marked on the tibialis anterior
muscle of the right leg, 5 cm lateral to the tibial tuberos-
ity [21].
The assessor will conduct a preliminary study of intra-
observer reliability for measuring the pressure pain
threshold at the evaluation points that will be used in
the study. Ten participants with chronic low back pain
will be recruited and assessed on two occasions that are
48 hours apart. The intra-evaluator reliability for the
measurement of the PPT will be estimated by calculating
the intraclass correlation coefficients (ICC type 3,2) for
the tibialis anterior muscle and the low back muscles.
During the PPT measurements, the circular probe of
the algometer (1-cm2 area) will be positioned perpen-
dicular to the skin and pressed at approximately 50 kPa/s
[22]. Participants will be asked to press a button when the
pressure or discomfort sensation becomes clearly painful.
Two pressure measurements (in kPa) will be collected
from each area at 30-s intervals.
Two demonstrations of the procedure will be
conducted for each participant in the extensor muscles
of the dominant forearm to ensure that the test is well-
understood. The mean values will be used for the lum-
bar region and the tibialis anterior muscle in the pain
threshold data analysis.
Current discomfort
The discomfort caused by the current will be assessed
using a 10-cm visual analogue scale (VAS) where the far
left end indicate “very comfortable” and the far right end
indicate “very uncomfortable” [23]. The discomfort will
be assessed at 30 minutes of stimulation in all sessions.
Roland-Morris disability questionnaire
Disability will be assessed by the Roland-Morris disabil-
ity questionnaire, which is widely used to assess thefunctional performance associated with low back pain
[24]. This instrument, which has been translated and
cross-culturally adapted for the Brazilian population
[25], consists of 24 items that describe the daily activities
that prove difficult for the patients to perform due to
low back pain. Many of the selected items are directly
correlated to a greater impairment in functional per-
formance. The patients will be instructed to verbally
state which items describe them on the particular assess-
ment day. The questionnaire will be applied on the first
and last days of treatment and at the 4-month follow-up
(conducted by telephone).
Global perceived effect scale
The global impression of recovery will be assessed
through the global perceived effect scale [26,27], which
has been translated and cross-culturally adapted into
Brazilian-Portuguese [17] and corresponds to an 11-
point scale ranging from −5 points (much worse) to 0
(no change) to 5 points (completely recovered). To
measure the global impression of recovery, the partici-
pants will be asked the following: “Compared with the
beginning of the first episode, how would you currently
describe your back?” Positive scores represent recovery,
and negative scores indicate a worsening of the symp-
toms. The scale will be applied before and after treat-
ment and at the 4-month telephone follow-up.
Sit-to-stand test
Functional performance will be assessed through a sit-
to-stand test. The patients will be instructed to sit and
stand 5 times from a chair with a backrest with their
arms crossed in front of them as quickly as they can
[28]. The test will be timed, and immediately after the
test, the patients will be questioned regarding the low
back pain experienced during the test. The test will be
performed during the first and last sessions prior to the
application of the current and after 30 minutes of
current stimulation.
Pain temporal summation
Temporal summation (TS) will be induced by an
analogue pressure algometer (FPK20, Wagner Instru-
ments, Greenwich, CT, USA) with a circular metal tip
measuring 0.79 cm2. The evaluator will be trained prior
to the data collection. The area selected for TS analysis
will be the site indicated as the lower pain threshold in
the low back algometry in which three stimuli per second
will be applied with a pressure of approximately 2 kg/s to
determine the best value for use in the TS test. Next, 10
stimuli will be performed using the algometer on the
selected region. Each TS stimulus will be maintained
for 1 second before being released, and the stimuli will
be spaced at 1-second intervals. A timer will be used to
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stimuli are maintained. Participants will be instructed
to report pain using the NRS, which will be posted on
the wall in front of them, at the first, fifth and tenth
stimulus [29]. The TS assessment will be performed prior
to initiating the treatment protocol and prior to current
application during the last session. To prevent sensitisa-
tion interference from the previously performed pain
pressure threshold assessment, the TS assessment will
begin 2 minutes after the PPT assessment.
Conditioned pain modulation
A cold pressor test will be used to assess the activation
of the conditioned pain modulation (CPM) [30]. The
conditioned stimulus will involve the immersion of the
lower limb on the ipsilateral side of the more painful
lumbar region. In cases of bilateral pain, the subject will
be instructed to report the most painful side [31]. If no
consensus can be reached regarding the most painful
side, the right leg will be used. The limb will be
immersed in a bucket containing water and ice at 4°C, 3
cm above the lateral malleolus of the ankle. The low
back pain intensity will be assessed after 20 seconds of
immersion using the NRS. The PPT at the low-back
algometry points will be recorded 30 seconds after
immersion. After removing the limb from the water, the
participants will be questioned regarding their foot pain
according to the NRS. A CPM activation test will be
performed on the first day of treatment prior to initiat-
ing the stimulation and on the last day of the session prior
to applying the current so that no interference occurs in
the CPM assessment immediately after stimulation.
Analgesic use
To assess the use of analgesics during the treatment, the
assessor will complete a record listing the days of the
week from the beginning of the treatment until the date
of the last session to note the use of analgesics or anti-
inflammatory drugs and their dosage during treatment
[10]. With this information, any reduction in the use of
medications during treatment can be assessed.
Procedure
Randomisation
After assessment, the patients will be referred to the
therapist responsible for the treatment, who will open
the sealed envelope prior to initiating the treatment to
determine in which group the patient will be included
(Group IFC 1 kHz, Group IFC 4 kHz or the IFC Placebo
Group). The randomisation of groups will be performed
using a computer-generated, random-number list com-
piled by an investigator not involved in the patient re-
cruitment or data collection. The group allocation will
be concealed by printing the group allocation onto cardsand sealing them in consecutively numbered opaque en-
velopes. The envelopes will be stored in a secure cabinet
accessibly only to the allocation investigator and will be
opened immediately prior to the intervention allocation.
Study-blinding assessment
Following the treatment and the follow-up assessments,
the therapist will ask the assessor if she believes that the
patient received interferential current or the placebo.
Additionally, the study participants will answer the same
questions justifying their answers. The answers to these
questions will be recorded and used to measure the
effectiveness of the study blinding [32].
Data analysis
Data will be double-entered and analysis will be
performed by a blinded statistician. All statistical proce-
dures will be conducted following the intention-to-treat
principles. Initially, the descriptive statistics will be used
for the studied variables. The data normalisation will be
analysed through a visual inspection of the histograms.
The between-group differences in the measurements of
the primary and secondary outcomes will be compared
via linear mixed models using the interaction terms
“group versus time” with a Tukey’s post-hoc test. For the
data analysis, the SPSS (statistical package for social sci-
ences) version 19.0 for Windows and Microsoft Excel
2007 will be used. All tests will be performed assuming a
significance level of p < 0.05.
Sample size calculation
To obtain the total number of participants in the present
study, the sample size was calculated to detect a differ-
ence of 1 point in the pain intensity outcome as mea-
sured by the numerical rating scale (NRS) (Costa et al.
2008) with a standard deviation of 1.47 points [33]. A
statistical power of 80%, a 5% alpha and a possible sam-
ple loss of up to 15% were considered. Therefore, 50 pa-
tients per group (150 in total) will be required (Minitab,
v. 15, State College, PA).
Discussion
The results of the present study will provide more accur-
ate estimates of the therapeutic effects and parameters
of interferential currents. The last systematic review on
the subject [12] suggests that new studies need to be
performed given the lack of high-quality research on the
use of interferential current in patients with low back
pain. This study can also provide information on the ef-
fects of the current on the pain mechanisms and the
optimum carrier frequency for use in the analgesia of
chronic, nonspecific low back pain. The results of the
present study may also assist physical therapists in mak-
ing clinical decisions based on a high-quality randomised
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crease the efficacy of low back pain treatments, thereby
increasing patients’ satisfaction and reducing the social
costs associated with these patients.
The strengths of the present study include a high qual-
ity design that supports strong clinical evidence. The use
of a placebo group enables an analysis of the therapy’s
effectiveness and aids in understanding the placebo ef-
fect. The study’s blinding assessment indicates the reli-
ability of the assessor and patient blinding. The present
study is the first to compare different IFC carrier fre-
quencies in patients suffering from pain and to assess
the long-term effects of the treatment.
The study’s limitations include the impossibility of
completely blinding the therapist due to the nature of
the intervention and the lack of a control group (under-
going no treatment) for comparison with the other
groups.
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